Key result
The CatBoost machine learning model predicted major adverse cardiac events in patients with end-stage renal disease, achieving an AUC of 0.745 (95% CI 0.605–0.83).
Why the study?
Patients with end-stage renal disease face an increased risk of major adverse cardiac events, highlighting the need for accurate risk prediction and personalized interventions.
Do machine learning models accurately predict major adverse cardiac events in patients with end-stage renal disease?
Observational
Do machine learning models accurately predict major adverse cardiac events in patients with end-stage renal disease?
Effect estimate: AUC 0.745 (95% CI 0.605-0.83)
Machine learning models, specifically CatBoost, can predict MACE in ESRD patients with moderate accuracy, identifying antiplatelet use, left ventricular hypertrophy grade, and serum albumin as key predictors.
ML models may aid MACE risk stratification in ESRD; leaves open whether they improve outcomes or decision-making in prospective use.
Background/Objectives: Patients with end-stage renal disease (ESRD) are at an increased risk of major adverse cardiac events (MACEs), highlighting the need for accurate risk prediction and personalized interventions. This study aims to develop and evaluate machine learning (ML) models to identify key predictive features and enhance clinical decision-making in MACE risk assessment. Methods: A dataset comprising 84 variables, including patient demographics, laboratory findings, and comorbidities, was analyzed using CatBoost, XGBoost, and LightGBM. Feature selection, cross-validation, and SHAP (SHapley Additive exPlanations) analyses were employed to improve model interpretability and clinical relevance. Results: CatBoost exhibited the highest predictive performance among the models tested, achieving an AUC of 0.745 (0.605–0.83) with balanced sensitivity and specificity. Key predictors of MACEs included antiplatelet use, the grade of left ventricular hypertrophy, and serum albumin levels. SHAP analysis enhanced the interpretability of model outputs, supporting clinician-led risk stratification. Conclusions: This study highlights the potential of ML-based predictive modeling to improve MACE risk assessment in patients with ESRD. The findings support the adoption of ML models in clinical workflows by integrating explainable AI methods to enable individualized treatment planning. Future integration with electronic health record systems may facilitate real-time decision-making and enhance patient outcomes.
No takes yet. Share an insight, caveat, or question.
Chuang et al. (2025) conducted an observational in End-stage renal disease (ESRD). Machine learning predictive modeling (CatBoost) was evaluated on Prediction of major adverse cardiac events (MACEs) (AUC 0.745, 95% CI 0.605-0.83). The CatBoost machine learning model predicted major adverse cardiac events in patients with end-stage renal disease, achieving an AUC of 0.745 (95% CI 0.605–0.83).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: